Published in Oncologist on April 06, 2009
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol (2012) 1.60
Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep (2011) 1.14
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs (2010) 1.09
Axitinib for the management of metastatic renal cell carcinoma. Drugs R D (2011) 1.01
Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis. Cancer Prev Res (Phila) (2010) 0.98
Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? J Thorac Dis (2011) 0.95
Integration of biomarkers including molecular targeted therapies in head and neck cancer. Head Neck Pathol (2010) 0.93
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol (2013) 0.92
Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer (2011) 0.90
Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery. Drug Des Devel Ther (2014) 0.90
YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Sci Rep (2014) 0.88
Identifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer model. Math Med Biol (2010) 0.87
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res (2015) 0.83
(3R,4S,5R)-Methyl 3,5-bis-[(tert-butyl-dimethyl-sil-yl)-oxy]-4-meth-oxy-cyclo-hex-1-ene-carboxyl-ate. Acta Crystallogr Sect E Struct Rep Online (2013) 0.83
Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line. Am J Cancer Res (2011) 0.83
Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One (2013) 0.81
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clin Cosmet Investig Dermatol (2013) 0.81
Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. Oncotarget (2016) 0.80
Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J Oncol (2011) 0.79
The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Oncotarget (2016) 0.79
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. Oncotarget (2015) 0.77
A Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity Prediction. PLoS One (2015) 0.77
Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. Sci Rep (2016) 0.76
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS One (2015) 0.76
Targeting angiogenesis for treatment of human cancer. Indian J Pharm Sci (2013) 0.76
Development of the rat model of lapatinib-induced diarrhoea. Scientifica (Cairo) (2014) 0.75
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma. Pharmaceuticals (Basel) (2010) 0.75
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt. Br J Cancer (2016) 0.75
ZD6474 coerces breast cancer for an apoptotic journey. Cancer Biol Ther (2010) 0.75
Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther (2015) 0.75
Incorporating VEGF-targeted therapy in advanced urothelial cancer. Ther Adv Med Oncol (2016) 0.75
A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients. Onco Targets Ther (2016) 0.75
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck (2015) 0.75
Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells. Cancer Sci (2017) 0.75
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene (2005) 6.04
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol (2010) 3.12
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets (2012) 2.55
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol (2005) 2.36
The role of the EGFR signaling in tumor microenvironment. J Cell Physiol (2008) 2.34
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol (2009) 2.30
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol (2004) 1.95
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer (2005) 1.81
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist (2006) 1.80
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer (2011) 1.78
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol (2009) 1.71
Leptin signaling in breast cancer: an overview. J Cell Biochem (2008) 1.71
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology (2007) 1.70
Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol (2004) 1.69
Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics (2010) 1.68
Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene (2005) 1.60
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery? Eur J Cardiothorac Surg (2011) 1.57
Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol (2002) 1.53
Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One (2011) 1.48
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more? J Clin Oncol (2004) 1.46
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol (2012) 1.43
Wasting lives: the effects of toxic waste exposure on health. The case of Campania, Southern Italy. Cancer Biol Ther (2011) 1.42
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer (2006) 1.41
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol (2011) 1.32
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One (2013) 1.32
A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res (2003) 1.32
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest (2003) 1.27
Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol (2005) 1.26
Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch (2012) 1.24
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer (2009) 1.24
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol (2004) 1.24
Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene (2005) 1.22
Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res (2006) 1.18
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol (2005) 1.16
Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer (2013) 1.10
Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst (2005) 1.10
Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem (2012) 1.10
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.10
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2015) 1.10
Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One (2010) 1.08
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer (2010) 1.06
Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat (2009) 1.06
Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol (2002) 1.04
Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol Immunother (2012) 1.03
EGFR-targeted therapy. Exp Cell Res (2011) 1.03
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. Oncotarget (2013) 1.03
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer (2014) 1.03
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. J Exp Clin Cancer Res (2009) 1.02
Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Cancer Treat Rev (2012) 1.01
Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica (2010) 1.00
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol (2007) 0.99
Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol (2008) 0.99
Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells. J Cell Physiol (2008) 0.99
Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo. J Cell Sci (2005) 0.99
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer (2012) 0.99
Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev (2012) 0.98
A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. Hum Pathol (2011) 0.98
Farnesyl transferase inhibitors in clinical development. Expert Opin Investig Drugs (2003) 0.98
Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol (2002) 0.98
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol (2003) 0.97
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer (2007) 0.97